Table 1 |
||||||||
|
Clinical and laboratory findings for 42 patients with ankylosing spondylitis treated with infliximab |
||||||||
|
Finding |
BASDAI |
BASMI |
BASFI |
PatGA |
PhysGA |
NRS-P |
ESR (mm/h) |
CRP (mg/l) |
|
|
||||||||
|
At time point 1a |
||||||||
|
|
||||||||
|
Mean ± SD |
2.5 ± 1.8** |
2.7 ± 2.0* |
2.9 ± 2.4** |
2.6 ± 1.5** |
2.6 ± 2.1** |
2.6 ± 2.1** |
10.5 ± 7.3** |
3.1 ± 4.2** |
|
Median |
2.4 |
2.0 |
2.5 |
4.0 |
2.0 |
2.0 |
8.0 |
1.1 |
|
Range |
0.0 - 6.8 |
0.0 - 7.0 |
0.0 - 8.3 |
0.0 - 8.0 |
0.0 - 4.0 |
0.0 - 7.0 |
2.0 - 32.0 |
0.0 - 19.0 |
|
|
||||||||
|
At time point 2a |
||||||||
|
|
||||||||
|
Mean ± SD |
6.1 ± 1.4** |
3.2 ± 2.2* |
5.8 ± 1.8** |
6.9 ± 2.1** |
7.0 ± 1.5** |
7.1 ± 1.7** |
31.5 ± 29.7** |
20.7 ± 23.7** |
|
Median |
6.2 |
3.0 |
5.7 |
7.0 |
7.0 |
7.0 |
23.0 |
14.0 |
|
Range |
4.0 - 9.2 |
0.0 - 9.0 |
1.2 - 9.1 |
4.0 - 10.0 |
4.0 - 10.0 |
0.0 - 10.0 |
4.0 - 150.0 |
0.3 - 126.0 |
|
|
||||||||
|
Change between time points 1 and 2 |
||||||||
|
|
||||||||
|
Mean ± SD |
3.6 ± 1.7 |
0.5 ± 1.5 |
2.9 ± 2.0 |
4.3 ± 1.9 |
4.4 ± 1.8 |
4.5 ± 2.2 |
21.0 ± 29.7 |
17.6 ± 23.4 |
|
Median |
3.6 |
0.5 |
2.5 |
4.0 |
4.0 |
4.0 |
12.0 |
11.5 |
|
Range |
-1.2 - 6.7 |
-4.0 - 3.0 |
-0.5 - 7.8 |
-2.0 - 8.0 |
-2.0 - 8.0 |
-1.0 - 8.0 |
-6.0 - 146.0 |
-6.3 - 123.0 |
|
|
||||||||
|
aTime point 1 is the time point at which infliximab treatment was discontinued; time point 2 is that when retreatment began. *P < 0.05, **P < 0.001, when means at time points 1 and 2 are compared. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NRS-P, numerical rating scale for pain; PatGA, patient's global assessment; PhysGA, physician's global assessment; SD, standard deviation. |
||||||||
|
Baraliakos et al. Arthritis Research & Therapy 2005 7:R439 doi:10.1186/ar1693 |
||||||||
